Literature DB >> 12064009

Failed antireflux surgery: surgical outcome of laparoscopic refundoplication in the elderly.

Thomas Kamolz1, Frank A Granderath, Tanja Bammer, Martin Pasiut, Rudolph Pointner.   

Abstract

BACKGROUND/AIMS: Antireflux surgery has a failure rate between 5 and 20%. Laparoscopic redo-surgery is feasible, but little is known about the surgical outcome in elderly patients. The aim of this prospective study was to evaluate early surgical experience and outcome, including quality of life, after laparoscopic refundoplication in patients older than 65 years.
METHODOLOGY: Eleven patients, mean age of 71 years (range: 65-78), underwent laparoscopic redo-surgery. Six patients had the former antireflux procedure performed by the open technique, one having had it twice, one had both laparoscopic and open antireflux procedures, and in 4 the primary intervention was performed laparoscopically. Quality of life was evaluated by using the Gastrointestinal Quality of Life Index. All patients were evaluated prior to surgery, and at 3 months and 12 months after laparoscopic refundoplication, as well as with esophageal manometry and 24-hour pH-monitoring.
RESULTS: Redo-procedures were completed laparoscopically in 10 patients. In one patient conversion to an open laparotomy was necessary because of severe bleeding from the spleen. One patient had an injury to the gastric wall, successfully managed laparoscopically. Postoperatively, one patient had moderate dysphagia for a period of two months, another had epigastric pain for the same period. Esophageal manometry and 24-hour pH-monitoring showed normal values in all patients after redo-surgery. Prior to redo-surgery, the mean Gastrointestinal Quality of Life Index was 85.2 points. Three months (mean: 119.8 points) and one year (mean: 119.2 points) after laparoscopic reoperation the general score increased significantly (P < 0.01) and attained the equivalent level of comparable healthy individuals (118.7 points).
CONCLUSIONS: Laparoscopic refundoplication in the elderly patient is feasible, safe and an effective treatment after failed antireflux surgery. Older patients with failed antireflux surgery have poor quality of life. Laparoscopic redo-surgery improves quality of life significantly to the level of healthy individuals and normalizes objective outcome criteria without any long-term restrictions in daily life.

Entities:  

Mesh:

Year:  2002        PMID: 12064009

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  6 in total

1.  Laparoscopic antireflux surgery in the elderly: surgical outcome and effect on quality of life.

Authors:  T Kamolz; R Pointner
Journal:  Surg Endosc       Date:  2002-09       Impact factor: 4.584

Review 2.  The impact of gastroesophageal reflux disease on quality of life.

Authors:  T Kamolz; R Pointner; V Velanovich
Journal:  Surg Endosc       Date:  2003-06-13       Impact factor: 4.584

3.  Laparoscopic antireflux surgery for the elderly: a surgical and quality-of-life study.

Authors:  Weu Wang; Ming-Te Huang; Po-Li Wei; Wei-Jei Lee
Journal:  Surg Today       Date:  2008-03-27       Impact factor: 2.549

4.  Revision of failed traditional fundoplication using EsophyX transoral fundoplication.

Authors:  Reginald C W Bell; Rachel J Hufford; Jacqueline Fearon; Katherine D Freeman
Journal:  Surg Endosc       Date:  2012-10-10       Impact factor: 4.584

Review 5.  Surgical reintervention after failed antireflux surgery: a systematic review of the literature.

Authors:  Edgar J B Furnée; Werner A Draaisma; Ivo A M J Broeders; Hein G Gooszen
Journal:  J Gastrointest Surg       Date:  2009-04-04       Impact factor: 3.452

6.  Long term quality of life after laparoscopic antireflux surgery for the elderly.

Authors:  Salvatore Tolone; Giovanni Docimo; Gianmattia Del Genio; Luigi Brusciano; Ignazio Verde; Simona Gili; Chiara Vitiello; Antonio D'Alessandro; Giuseppina Casalino; Francesco Lucido; Nicola Leone; Raffaele Pirozzi; Roberto Ruggiero; Ludovico Docimo
Journal:  BMC Surg       Date:  2013-10-08       Impact factor: 2.102

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.